Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis

ObjectiveTo determine the efficacy and safety of using natural platelet-activating factor receptor antagonist (PAFra), BN 52021, to treat patients with severe Gram-negative bacterial sepsis.DesignA prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial.SettingFifty-nin